InoLife Technologies, Inc., a service-based healthcare products development, integration and marketing company, recently announced that it will market its proprietary metabolizing test to physicians and practitioners to identify how a patient’s genetic makeup may affect the body’s response to Plavix (colpidogrel). Plavix, the second-best selling drug in the world, reduces the risk of heart attack, stroke, and cardiovascular death in patients with cardiovascular disease by making platelets less likely to form blood clots.

The Food and Drug Administration recently announced that Plavix must now carry a so-called “black box” warning label after a study revealed that patients with genetic variation were “3.58 times more likely to have a fatal stroke or myocardial infarction.” InoLife Technologies feels that this is an important test for those who take Plavix or who may need to take Plavix in the future. The company is very pleased that by addressing the black box warning, those who can be helped by this medication will be.

“We determined that there are three critical problems that can lead to a level of non-response to Plavix,” said Dr. Frederic J. Vagnini, M.D., FACS, a board-certified cardiovascular surgeon. “First, in anyone an abnormality may be present within a gene abbreviated as CYP2C19 (and other variants) which significantly increases the risk of stroke or death due to clotting failure. Second, there are different variants or mutations between ethnic groups; some studies have indicated that one in three Caucasians and 40 percent of Asian of African-American populations have this abnormality.”

Dr. Vagnini stated, “Among clinicians there have been discussions centering on differing dosing approaches. Perhaps the most important result of InoLife’s DNA test is that each patient will be able to have an individually tailored course of treatment since some require longer periods on it.”

For more information, please visit www.inolifetech.com.